UAE - Mubasher: The UAE's Mubadala Investment Company and New York-based Kohlberg & Company have signed an agreement to acquire the majority stake in PCI Pharma Services, a pharmaceutical global supply chain solutions provider and a subsidiary of Partners Group.
Under the agreement, Switzerland-headquartered Partners Group, the global private markets investment manager, will sell the majority of its stake in PCI and own a minority equity stake in the company, according to a recent press release.
Headquartered in Philadelphia, Pennsylvania in the US, PCI Pharma Services offers various integrated pharmaceutical supply chain solutions, including drug development, commercial launch, and ongoing supply delivery.
PCI has 25 GMP facilities across six countries, with 3,900 people employees.
The private equity firm KohIberg and Mubadala will collaborate with PCl's management team to add new capabilities to the company to meet the future demands of biopharmaceutical customers.
Commenting on the agreement, the CEO of PCI, Salim Haffar, said: "Kohlberg brings considerable successful experience in the biopharmaceuticals and medical device areas, and I am thrilled to be continuing with them to accelerate the growth of our commercial, clinical trial services, and development manufacturing businesses under this new alliance."
Meanwhile, the Head of Pharma and Medtech at Mubadala, Camilla Macapili Languille, noted: "Outsourced pharmaceutical services has been a key investment theme for us over the past few years, and we are excited to be partnering with one of the global leaders in this industry."
